Last reviewed · How we verify
Tocolytics
Tocolytics is a Small molecule drug developed by Chulalongkorn University. It is currently in Phase 1 development.
Tocolytics are medications used to suppress premature labor, with the goal of postponing delivery long enough for the administration of glucocorticoids to be effective. These medications are typically used when delivery would result in premature birth, which accounts for 70% of neonatal deaths.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tocolytics |
|---|---|
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fetal Cardiac Effects of Tocolytic Nifedipine and Magnesium Sulfate
- Comparison in Cervical Length and Prolongation of Gestation Age on Vaginal Progesterone Administration to Pregnant Women After the Acute Phase of Threatened Preterm Birth (NA)
- To Optimize Antenatal Management of Women With Pre Term Labor Using Amniocentesis (PHASE3)
- Extra Hospital Delivery Outside Medical Presence. (NA)
- Magnesium Sulphate in Premature Rupture of Membranes
- HUMAN CHORIONIC GONADOTROPIN (HcG) VS MAGNESIUM SULPHATE (MgSo4) AS A TOCOLYTIC AGENT- A RANDOMIZED CONTROLLED TRIAL (NA)
- High Versus Low Dose of Magnesium Sulfate as Initial Tocolytic Agent for Preterm Labour in Symptomatic Placenta Previa. (PHASE2)
- In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tocolytics CI brief — competitive landscape report
- Tocolytics updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI
Frequently asked questions about Tocolytics
What is Tocolytics?
Who makes Tocolytics?
What development phase is Tocolytics in?
Related
- Manufacturer: Chulalongkorn University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing